An observational study in Acute Heart Failure, sponsored by University of Monastir. Recruiting at 1 site in Tunisia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-22.
Sponsored by University of Monastir · Observational
Heart failure (HF) is the leading cause of hospitalization ,rehospitalization and mortality for adults over 65 years of age.
This study aimed to assess mortality, and hospitalization rates at 30 days and one year after dicharge of patients with heart failure (HF) with reduced ejection fraction (HFrEF) compared to HF with preserved ejection fraction (HFpEF).
This study included all patients ,with either reduced ejection fraction (HFrEF) defined as LVEF \<45% or preserved ejection fraction (HFpEF) defined as LVEF ≥45% ,admitted to the ED of Monastir from 2009 with a principal discharge diagnosis code for HF. The diagnosis of HF categories should rely on the recent transthoracic echocardiographic findings and clinical judgement according to the guidelines.Collected data include clinical features biological markers (BNP or NTpro BNP) and echocardiography findings. The diagnosis of HF categories should rely on the recent transthoracic echocardiographic findings and clinical judgement according to the guidelines. A follow-up period of at least 1 year was required to notice all cause mortality and preferably HF-specific rehospitalization .
Exclusion Criteria:
Inability to follow instructions or comply with follow-up procedures.
Death or readmission rates
A composite outcome of Death or readmission within 365 days of hospital discharge
Time frame: within 365 days after hospital discharge
Death or readmission rates
A composite outcome of Death or readmission within 30 days of hospital discharge
Time frame: within 30 days after hospital discharge
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Monastir